Home » Stocks » ACHL

Achilles Therapeutics plc (ACHL)

Stock Price: $11.72 USD -0.21 (-1.72%)
Updated Jun 17, 2021 12:56 PM EDT - Market open
Market Cap 475.88M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 40.62M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 17
Last Price $11.72
Previous Close $11.92
Change ($) -0.21
Change (%) -1.72%
Day's Open 11.83
Day's Range 11.72 - 12.41
Day's Volume 2,462
52-Week Range 11.42 - 18.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

- Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned -

1 month ago - GlobeNewsWire

LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced...

1 month ago - GlobeNewsWire

LONDON, United Kingdom, May 03, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors,...

1 month ago - GlobeNewsWire

LONDON, April 10, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today present...

2 months ago - GlobeNewsWire

LONDON, April 06, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announc...

2 months ago - GlobeNewsWire

Achilles Therapeutics plc (NASDAQ: ACHL) announced the pricing of its IPO on the Nasdaq that will raise US$175.5mln (£127.8mln). The clinical-stage biopharma, which is developing precision T cell therap...

2 months ago - Proactive Investors

LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announc...

2 months ago - GlobeNewsWire

Achilles Therapeutics, a Phase 1/2 biotech developing precision T cell therapies for solid tumors, filed on Monday with the SEC to raise up to $100 million in an initial public offering.

3 months ago - NASDAQ

Achilles Therapeutics plc has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

About ACHL

Achilles Therapeutics is a clinical stage immuno-oncology biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumors. Our platform enables us to identify mutations formed early in the development of a cancer that give rise to antigens. We refer to this novel class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, we have developed a proprietary bioinformatic platform called PELEUS. This platform employs sophisticated statistical algorithms trained on the uniqu... [Read more...]

Industry
Biotechnology
IPO Date
Mar 31, 2021
CEO
Iraj Ali, Ph.D.
Employees
153
Stock Exchange
NASDAQ
Ticker Symbol
ACHL
Full Company Profile

Financial Performance

Financial Statements